Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses

  1. Omer Turker,
  2. Kamil Kumanlioglu1,
  3. Inanc Karapolat2 and
  4. Ismail Dogan
  1. Thyroidology Unit, Department of Nuclear Medicine, GATA Haydarpasa, Istanbul, Turkey
  2. 1Department of Nuclear Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
  3. 2Department of Nuclear Medicine, Sifa Hospital, Izmir, Turkey
  1. (Requests for offprints should be addressed to O Turker; Email: otturker{at}
  1. Figure 1

    TPOAb concentrations at the beginning of the study and 3 months after treatment with 200 mg l-selenomethionine/day (group S2) or placebo (group C). P values were calculated by Wilcoxon’s matched pairs, signed-ranks test.

  2. Figure 2

    Dose-response curves of subgroups. Note the concordance in decrement rates in groups S2, S22 and S212, who received 200 mg l-selemethionine/day, and the decreased response in group S222. Rising serum concentrations of TPOAb in group S21 clearly confirms the ineffectiveness of 100 mg l-selemethionine/day.

| Table of Contents